メインのコンテンツにスキップする

申し訳ございませんが、お客様のブラウザには完全に対応しておりませんオプションがありましたら、新しいバージョンにアップグレードするか、 Mozilla Firefox、 Microsoft Edge、Google Chrome、またはSafari 14以降をお使いください。これらが利用できない場合、またサポートが必要な場合は、フィードバックをお送りください。

この新ホームページへのフィードバックを歓迎します。ご意見をお寄せください新しいタブ/ウィンドウで開く

Elsevier
論文を投稿する
Video

Clinicalkey AI in action: What are indications for plasma exchange in severe babesiosis

| 2 分経過

ClinicalKey AI combines trusted, evidence-based clinical content with conversational search powered by generative AI to support clinicians in delivering high-quality patient care.  Clinicians gain a powerful ally with ClinicalKey AI by providing quick access to trusted clinical knowledge and allowing them to focus on what truly matters, quality patient care. Interested healthcare organizations can contact us today to learn more.  

ClinicalKey AI Query: What are indications for plasma exchange in severe babesiosis

Plasma exchange, also known as exchange blood transfusion, is indicated in severe babesiosis in cases of high-grade parasitemia (10% or more of erythrocytes), severe hemolytic anemia (less than 10 g/dL), pulmonary, renal, or hepatic impairment, and Babesia divergens infection.[1-2]

  • Exchange blood transfusion is used to rapidly decrease parasite burden and clear toxic byproducts from circulation.[1]

  • The procedure can be either partial or complete, depending on the severity of the disease.[1]

  • It is capable of reducing parasitemia by 90%, and limited data suggest early use (within approximately 1.5 days after presentation) of exchange transfusion may prevent organ dysfunction.[1]

  • In addition to antibiotic treatment, partial or complete red cell exchange transfusion should be considered in severely ill patients with parasitemias in excess of 10%, evidence of severe hemolysis, or organ compromise.[3]

  • A systematic review suggests that apheresis may be a useful adjunct in the treatment of patients hospitalized for babesiosis.[4]

  1. Babesiosis.新しいタブ/ウィンドウで開く  Elsevier ClinicalKey  Clinical Overview 

  2. Babesiosis and Other Protozoan Diseases.新しいタブ/ウィンドウで開く  Telford, Sam R., Krause, Peter J. In Goldman-Cecil Medicine (pp. 2151). 

  3. Safety and Effectiveness of Apheresis in the Treatment of Infectious Diseases: A Systematic Review.新しいタブ/ウィンドウで開く  Odedra A, Lalloo DG, Kennedy G, Llewellyn S, McCarthy JS.  The Journal of Infection. 2019;79(6):513-520. doi:10.1016/j.jinf.2019.09.014. 

Answer generated on April 2, 2024 

Note: User acknowledges that these materials are provided for use at no charge as part of Elsevier’s efforts to support healthcare providers and patients. The information contained within the website is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill and judgment of healthcare professionals involved in patient care. The content within this page may not be re-used, modified or re-distributed without prior written permission.